Pfizer Basic EPS 2010-2024 | PFE
Pfizer annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Pfizer basic eps for the quarter ending September 30, 2024 was $0.79, a 288.1% decline year-over-year.
- Pfizer basic eps for the twelve months ending September 30, 2024 was $0.76, a 58.92% decline year-over-year.
- Pfizer annual basic eps for 2023 was $0B, a 93.2% decline from 2022.
- Pfizer annual basic eps for 2022 was $0.006B, a 42.6% increase from 2021.
- Pfizer annual basic eps for 2021 was $0.004B, a 137.58% increase from 2020.
| Pfizer Annual Basic EPS |
| 2023 |
$0.38 |
| 2022 |
$5.59 |
| 2021 |
$3.92 |
| 2020 |
$1.65 |
| 2019 |
$2.88 |
| 2018 |
$1.90 |
| 2017 |
$3.57 |
| 2016 |
$1.18 |
| 2015 |
$1.13 |
| 2014 |
$1.44 |
| 2013 |
$3.23 |
| 2012 |
$1.96 |
| 2011 |
$1.28 |
| 2010 |
$1.03 |
| 2009 |
$1.23 |
| Pfizer Quarterly Basic EPS |
| 2024-09-30 |
$0.79 |
| 2024-06-30 |
$0.01 |
| 2024-03-31 |
$0.55 |
| 2023-12-31 |
$-0.59 |
| 2023-09-30 |
$-0.42 |
| 2023-06-30 |
$0.41 |
| 2023-03-31 |
$0.98 |
| 2022-12-31 |
$0.88 |
| 2022-09-30 |
$1.54 |
| 2022-06-30 |
$1.77 |
| 2022-03-31 |
$1.40 |
| 2021-12-31 |
$0.61 |
| 2021-09-30 |
$1.45 |
| 2021-06-30 |
$0.99 |
| 2021-03-31 |
$0.87 |
| 2020-12-31 |
$0.16 |
| 2020-09-30 |
$0.26 |
| 2020-06-30 |
$0.63 |
| 2020-03-31 |
$0.60 |
| 2019-12-31 |
$-0.10 |
| 2019-09-30 |
$1.38 |
| 2019-06-30 |
$0.91 |
| 2019-03-31 |
$0.69 |
| 2018-12-31 |
$-0.06 |
| 2018-09-30 |
$0.70 |
| 2018-06-30 |
$0.66 |
| 2018-03-31 |
$0.60 |
| 2017-12-31 |
$2.05 |
| 2017-09-30 |
$0.48 |
| 2017-06-30 |
$0.52 |
| 2017-03-31 |
$0.52 |
| 2016-12-31 |
$0.13 |
| 2016-09-30 |
$0.22 |
| 2016-06-30 |
$0.34 |
| 2016-03-31 |
$0.49 |
| 2015-12-31 |
$-0.03 |
| 2015-09-30 |
$0.35 |
| 2015-06-30 |
$0.43 |
| 2015-03-31 |
$0.38 |
| 2014-12-31 |
$0.20 |
| 2014-09-30 |
$0.42 |
| 2014-06-30 |
$0.46 |
| 2014-03-31 |
$0.36 |
| 2013-12-31 |
$0.46 |
| 2013-09-30 |
$0.39 |
| 2013-06-30 |
$2.00 |
| 2013-03-31 |
$0.38 |
| 2012-12-31 |
$0.85 |
| 2012-09-30 |
$0.43 |
| 2012-06-30 |
$0.44 |
| 2012-03-31 |
$0.24 |
| 2011-12-31 |
$0.19 |
| 2011-09-30 |
$0.48 |
| 2011-06-30 |
$0.33 |
| 2011-03-31 |
$0.28 |
| 2010-12-31 |
$0.36 |
| 2010-09-30 |
$0.11 |
| 2010-06-30 |
$0.31 |
| 2010-03-31 |
$0.25 |
| 2009-12-31 |
$0.05 |
| 2009-09-30 |
$0.43 |
| 2009-06-30 |
$0.34 |
| 2009-03-31 |
$0.41 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
